Yahoo Web Search

    • Real-world Use of and Spending on New Oral Targeted Cancer Drugs in the US, 2011-2018

      Journal of the American Medical Association· 3 days ago

      ...sectional study among 37 348 patients who received 1 or more of 44 new oral targeted cancer drugs, the proportion of patients receiving drugs without documented overall survival benefit increased from 13% in 2011 to 59% in 2018, accounting for 52% of the $3.5 billion estimated cumulative spending...